Recombinant Adeno-Associated Virus Vectors Induce Functionally Impaired Transgene Product-Specific CD8+ T Cells in Mice
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors were used in human trials as carriers of vaccines for HIV-1 after encouraging preclinical results. However, the clinical trials yielded disappointing results. Here we demonstrated that in mice, rAAV vectors expressing the gene encoding HIV-1 gag stimulated gag-specific CD8(+) T cells, but these T cells failed to expand after a booster immunization with a replication-defective adenoviral (Ad) vector also expressing gag. We tested rAAV vectors of different serotypes expressing HIV-1 gag for induction of transgene product-specific CD8(+) T cells and found that the immunoinhibitory effect of rAAV priming observed with different AAV serotypes was transgene product specific, was independent of the interval between prime and boost, and extended to boosts with vaccine modalities other than Ad vectors. rAAV vector-induced CD8(+) T cells proliferated poorly, produced low levels of IFN-gamma in response to gag stimulation, and upregulated immunoinhibitory molecules. These T cells did not protect efficiently against challenge with a surrogate pathogen. Finally, we showed that the impaired proliferative capacity of the T cells was caused by persistence of the antigen-encoding rAAV vectors and could be reversed by placing the CD8(+) T cells in an antigen-free environment. Our data suggest that rAAV vectors induce functionally impaired T cells and could dampen the immune response to a natural infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These often induce functionally impaired CD8+ T cells against the transgene product with a reduced cytotoxic and proliferative capacity (50), ultimately undergoing apoptosis (51).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 5×
“CD8+ T cells that are continuously immersed in antigen become exhausted, as attested by loss of proliferation to antigen, secretion of cytokines, target cell lysis (35, 75), and upregulation of PD-1 and other negative costimulators; blockade of the PD-1/ PD-L1/2 pathway through antibodies can restore functionality of…”
BackgroundMethodInfluentialPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · cited 2×
“Groups of mice were immunized with 1011 gc rAAV2/7gag and then treated with 200 μg anti-PD-1 antibody, twice prior to boost and 3 times after boost, 3 days apart, as described previously (36, 50, 51).”
MethodCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., & Sacks, D. L. (2002) · Nature · doi:10.1038/nature01152 · Cited by 1,725
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635 · cited 1×
“We could not detect IFN-γ–producing CD4+ T cells in rAAVgagimmunized mice by ELISpot assays (data not shown), and an impaired memory response has previously been described for CD8+ T cells that are activated without T help (65, 66).”
BackgroundThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528 · cited 1×
“It was shown in the chronic LCMV infection model that blockade of the PD-1/program death–ligand 1 (PD-1/PD-L1) pathway reinstates functionality to exhausted CD8+ T cells (36, 52).”
BackgroundNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“Several AAV serotypes have been isolated from primates (16, 17), as well as other animals, and have been vectored and tested as gene delivery vehicles (18).”
BackgroundRequirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460 · cited 1×
“We could not detect IFN-γ–producing CD4+ T cells in rAAVgagimmunized mice by ELISpot assays (data not shown), and an impaired memory response has previously been described for CD8+ T cells that are activated without T help (65, 66).”
BackgroundClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Several AAV serotypes have been isolated from primates (16, 17), as well as other animals, and have been vectored and tested as gene delivery vehicles (18).”
BackgroundNatural regulatory T cells in infectious disease
Belkaid, Y., & Rouse, B. T. (2005) · Nature Immunology · doi:10.1038/ni1181 · Cited by 1,035
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Dendritic Cells: Translating Innate to Adaptive Immunity
Steinman, R. M., & Hemmi, H. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-32636-7_2 · Cited by 844 · cited 1×
“rAAV vectors do not induce a strong inflammatory response in vivo, and in vitro experiments have shown that they fail to drive maturation of immature DCs (32), which in turn are viewed as a prerequisite for induction of primary cell-mediated immune responses (33).”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“Humans commonly carry neutralizing antibodies to human serotypes of AAV such as AAV2 and AAV1 as a result of natural infections (61), and such antibodies have been shown in gene therapy trials to reduce gene transfer (61, 62).”
BackgroundSelf-citationRegulatory T cells: friend or foe in immunity to infection?
Mills, K. H. G. (2004) · Nature Reviews Immunology · doi:10.1038/nri1485 · Cited by 702
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms
Bessis, N., GarciaCozar, F. J., & Boissier, M.-C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302364 · Cited by 633
Sedy, J. R., Gavrieli, M., Potter, K. G., Hurchla, M. A., Lindsley, R. C., Hildner, K., Scheu, S., Pfeffer, K., Ware, C. F., Murphy, T. L., et al. (2005) · Nature Immunology · doi:10.1038/ni1144 · Cited by 632
CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses
Suvas, S., Kumaraguru, U., Pack, C. D., Lee, S., & Rouse, B. T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030171 · Cited by 527
Herzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474 · cited 2×
“To test whether persistence of the rAAV2/7gag vector, which would be expected to remain transcriptionally active as has been shown for other rAAV vectors (55, 56), affected the gag-specific CD8+ T cell response, mice were immunized with 1011 gc AAV2/7gag or 1010 vp AdHu5gag as a control.”
BackgroundCD27 and CD70 in T cell and B cell activation
Borst, J., Hendriks, J., & Xiao, Y. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.04.004 · Cited by 419
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
Freeman, G. J., Wherry, E. J., Ahmed, R., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061800 · Cited by 399 · cited 2×
“Groups of mice were immunized with 1011 gc rAAV2/7gag and then treated with 200 μg anti-PD-1 antibody, twice prior to boost and 3 times after boost, 3 days apart, as described previously (36, 50, 51).”
MethodWang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 367 · cited 1×
“In contrast, AAV vectors containing double-stranded DNA express their transgene product without delay (77).”
BackgroundKohm, A. P., McMahon, J. S., Podojil, J. R., Begolka, W. S., DeGutes, M., Kasprowicz, D. J., Ziegler, S. F., & Miller, S. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3301 · Cited by 332 · cited 1×
“rAAV2/7gag-immunized mice were treated with PC61, an antibody to CD25, to functionally inactivate the CD4+CD25+ regulatory cells (31) prior to the AdC68gag boost.”
MethodJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Adeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · cited 1×
“Several AAV serotypes have been isolated from primates (16, 17), as well as other animals, and have been vectored and tested as gene delivery vehicles (18).”
BackgroundMcHugh, R. S., & Shevach, E. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.5979 · Cited by 319
CD44 contributes to T cell activation.
Huet, S., Groux, H., Caillou, B., Valentin, H., Prieur, A. M., & Bernard, A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.3.798 · Cited by 318 · cited 1×
“Expression of CD44, a cell surface glycoprotein involved with lymphocyte activation (37, 38), on tet+CD8+ T cells from the different mice was indistinguishable (data not shown).”
BackgroundDual role of the CD44 molecule in T cell adhesion and activation.
Shimizu, Y., Van Seventer, G. A., Siraganian, R., Wahl, L., & Shaw, S. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.8.2457 · Cited by 318 · cited 1×
“Expression of CD44, a cell surface glycoprotein involved with lymphocyte activation (37, 38), on tet+CD8+ T cells from the different mice was indistinguishable (data not shown).”
BackgroundBalancing co-stimulation and inhibition with BTLA and HVEM
Murphy, K. M., Nelson, C. A., & Šedý, J. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1917 · Cited by 309
Mendez, S., Reckling, S. K., Piccirillo, C. A., Sacks, D., & Belkaid, Y. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040298 · Cited by 296
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264 · cited 1×
“AAV’s single-strand DNA genome of 4,700 nucleotides is flanked by 145 base palindromic inverted terminal repeat (ITR) elements (12, 13).”
BackgroundAn HIV Vaccine — Evolving Concepts
Johnston, M. I., & Fauci, A. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra066267 · Cited by 257
Gonzalez, L. C., Loyet, K. M., Calemine-Fenaux, J., Chauhan, V., Wranik, B., Ouyang, W., & Eaton, D. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409071102 · Cited by 252
Immune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241 · cited 1×
“rAAVs, unlike other viral vectors, fail to induce a strong inflammatory response and production of proinflammatory cytokines by the innate immune system (63).”
BackgroundIL-10, T cell exhaustion and viral persistence
Blackburn, S. D., & Wherry, E. J. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.02.006 · Cited by 219 · cited 3×
“During chronic LCMV infection, CD8+ T cells cease to be lytic and lose their ability to secrete cytokines and proliferate upon antigenic stimulation (35).”
BackgroundTatsis, N., Fitzgerald, J. C., Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., Lin, S.-W., Bian, A., Xiang, Z. Q., Iparraguirre, A., et al. (2007) · Blood · doi:10.1182/blood-2007-02-062117 · Cited by 218 · cited 1×
“CD62L that is rapidly upregulated on CD8+ T cells stimulated by an acute infection, such as with LCMV, emerge very slowly on AdC68-induced CD8+ T cells because Ad vectors persist at low levels for prolonged times in lymphocytes, which delays progression of CD8+ T cells into central memory (43).”
BackgroundSelf-citationA Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag
Fitzgerald, J. C., Gao, G.-P., Reyes-Sandoval, A., Pavlakis, G. N., Xiang, Z. Q., Wlazlo, A. P., Giles-Davis, W., Wilson, J. M., & Ertl, H. C. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1416 · Cited by 216 · cited 1×
“rAAV2/7gag-primed mice were boosted with a chimpanzee-derived Ad vector, Ad chimpanzee serotype 68 (AdC68) (25, 26), that also expressed a codon-optimized truncated gag (AdC68gag).”
MethodSelf-citationImmune Responses to Adeno-Associated Virus Vectors
Zaiss, A., & Muruve, D. (2005) · Current Gene Therapy · doi:10.2174/1566523054065039 · Cited by 213
Xiang, Z., Gao, G., Reyes-Sandoval, A., Cohen, C. J., Li, Y., Bergelson, J. M., Wilson, J. M., & Ertl, H. C. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2667-2675.2002 · Cited by 195 · cited 1×
“rAAV2/7gag-primed mice were boosted with a chimpanzee-derived Ad vector, Ad chimpanzee serotype 68 (AdC68) (25, 26), that also expressed a codon-optimized truncated gag (AdC68gag).”
MethodSelf-citationBartholdy, C., Christensen, J. P., Wodarz, D., & Thomsen, A. R. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10304-10311.2000 · Cited by 140 · cited 1×
“CD8+ T cells that are continuously immersed in antigen become exhausted, as attested by loss of proliferation to antigen, secretion of cytokines, target cell lysis (35, 75), and upregulation of PD-1 and other negative costimulators; blockade of the PD-1/ PD-L1/2 pathway through antibodies can restore functionality of…”
BackgroundGene transfer into skeletal muscle using novel AAV serotypes
Louboutin, J., Wang, L., & Wilson, J. M. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.686 · Cited by 130
Manning, W. C., Paliard, X., Zhou, S., Pat Bland, M., Lee, A. Y., Hong, K., Walker, C. M., Escobedo, J. A., & Dwarki, V (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7960-7962.1997 · Cited by 122
Dobrzynski, E., Fitzgerald, J. C., Cao, O., Mingozzi, F., Wang, L., & Herzog, R. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508685103 · Cited by 105 · cited 1×
“Previous gene therapy studies have shown that regulatory CD4+ T cells induce tolerance to the transgene product (29, 30).”
BackgroundLong-Term Efficacy of Adeno-Associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice
Sarkar, R., Mucci, M., Addya, S., Tetreault, R., Bellinger, D. A., Nichols, T. C., & Kazazian, H. H. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.427 · Cited by 103
Xin, K.-Q., Urabe, M., Yang, J., Nomiyama, K., Mizukami, H., Hamajima, K., Nomiyama, H., Saito, T., Imai, M., Monahan, J., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401750214276 · Cited by 101
Shibaki, A., & Katz, S. (2002) · Experimental Dermatology · doi:10.1034/j.1600-0625.2002.110204.x · Cited by 95 · cited 1×
“To bypass potential lack of DC maturation upon rAAV vaccination, we immunized mice with rAAV2/7gag mixed with adjuvants that can drive DC maturation, such as incomplete Freund’s adjuvant (34) (Figure 8) or poly(I:C) (data not shown), a TLR-3 ligand.”
MethodQiu, J.-T. T., Song, R., Dettenhofer, M., Tian, C., August, T. J., Felber, B. K., Pavlakis, G. N., & Yu, X.-F. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9145-9152.1999 · Cited by 83
Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
Hensley, S. E., Cun, A. S., Giles-Davis, W., Li, Y., Xiang, Z., Lasaro, M. O., Williams, B. R. G., Silverman, R. H., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300024 · Cited by 78 · cited 1×
“Furthermore, we reported previously that Ad vectors induce a potent transgene product–specific CD8+ T cell response even under conditions in which they are unable to induce DC maturation (64).”
BackgroundSelf-citationLiu, X., Voulgaropoulou, F., Chen, R., Johnson, P. R., & Clark, K. R. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0132 · Cited by 78 · cited 1×
“The ITRs are minimally required in cis to generate rAAV vectors in which all other viral sequences are supplied in trans (14, 15).”
BackgroundGao, G.-P., Lu, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R., & Wilson, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.00526-06 · Cited by 78
Determination of Specific CD4 and CD8 T Cell Epitopes after AAV2- and AAV8-hF.IX Gene Therapy
Chen, J., Wu, Q., Yang, P., Hsu, H.-C., & Mountz, J. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.006 · Cited by 76 · cited 1×
“This pathway also seems unlikely to explain the impaired CD8+ T cell response to rAAV vectors, because both the AAV capsid antigen (67) and the transgene product carry epitopes for CD4+ T cells (68), and we showed that rAAV vectors induced T cell–dependent antibody responses.”
BackgroundWu, L., Kong, W.-P., & Nabel, G. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8024-8031.2005 · Cited by 75 · cited 1×
“This pathway also seems unlikely to explain the impaired CD8+ T cell response to rAAV vectors, because both the AAV capsid antigen (67) and the transgene product carry epitopes for CD4+ T cells (68), and we showed that rAAV vectors induced T cell–dependent antibody responses.”
BackgroundRep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap
Gao, G.-P., Lu, F., Sanmiguel, J. C., Tran, P. T., Abbas, Z., Lynd, K. S., Marsh, J., Spinner, N. B., & Wilson, J. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2001.0591 · Cited by 73 · cited 1×
“The ITRs are minimally required in cis to generate rAAV vectors in which all other viral sequences are supplied in trans (14, 15).”
BackgroundMobley, J. L., Rigby, S. M., & Dailey, M. O. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.12.5443 · Cited by 69 · cited 1×
“CD62L downregulated in effector or effector memory cells (42) was high on rAAV2/7gag- and AdC68gag-induced CD8+ T cells even when tested months after immunization (data not shown).”
BackgroundQiu, J.-T. T., Liu, B., Tian, C., Pavlakis, G. N., & Yu, X.-F. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.5997-6005.2000 · Cited by 65 · cited 1×
“with Vacgag to allow for its replication in the animals’ ovaries (28).”
BackgroundSafety of adeno-associated virus gene therapy vectors: a current evaluation
Monahan, P. E., Jooss, K., & Sands, M. S. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.79 · Cited by 62 · cited 1×
“rAAV vectors used in clinical gene therapy trials were well tolerated (2, 23).”
MethodVeron, P., Allo, V., Rivière, C., Bernard, J., Douar, A.-M., & Masurier, C. (2007) · Journal of Virology · doi:10.1128/jvi.02516-06 · Cited by 58 · cited 6×
“We attributed this to the presence of low levels of mature DCs that can be detected in naive mice and argue that these mature DCs may also facilitate stimulation of hitherto antigen-inexperienced CD8+ T cells to an antigen presented by rAAV vectors.”
BackgroundInfluentialLiu, Y.-L., Mingozzi, F., Rodriguéz-Colôn, S. M., Joseph, S., Dobrzynski, E., Suzuki, T., High, K. A., & Herzog, R. W. (2004) · Human Gene Therapy · doi:10.1089/1043034041648453 · Cited by 54 · cited 1×
“They were shown to achieve sustained expression of the therapeutic protein in target tissues of experimental animals (4).”
BackgroundRey, J., Giustiniani, J., Mallet, F., Schiavon, V., Boumsell, L., Bensussan, A., Olive, D., & Costello, R. T. (2006) · European Journal of Immunology · doi:10.1002/eji.200635935 · Cited by 50 · cited 1×
“In addition, at some late time points tested, CD244 (2B4), an NK cell marker found on some T cell populations (53, 54), was upregulated on a subset of rAAV2/7-induced CD8+ T cells as well as on gag-specific CD8+ T cells from mice that had received the prime/boost regimen (data not shown).”
BackgroundRecombinant adeno-associated virus vectors for gene therapy
Conlon, T. J., & Flotte, T. R. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1093 · Cited by 49 · cited 2×
“To test whether persistence of the rAAV2/7gag vector, which would be expected to remain transcriptionally active as has been shown for other rAAV vectors (55, 56), affected the gag-specific CD8+ T cell response, mice were immunized with 1011 gc AAV2/7gag or 1010 vp AdHu5gag as a control.”
BackgroundGene therapy: Recombinant adeno-associated virus vectors
Smith-Arica, J. R., & Bartlett, J. S. (2001) · Current Cardiology Reports · doi:10.1007/s11886-001-0009-x · Cited by 47 · cited 1×
“AAV’s single-strand DNA genome of 4,700 nucleotides is flanked by 145 base palindromic inverted terminal repeat (ITR) elements (12, 13).”
BackgroundCD4+ CD25+ regulatory T cells inhibit immune-mediated transgene rejection
Gross, D.-A., Leboeuf, M., Gjata, B., Danos, O., & Davoust, J. (2003) · Blood · doi:10.1182/blood-2003-05-1454 · Cited by 45 · cited 1×
“Previous gene therapy studies have shown that regulatory CD4+ T cells induce tolerance to the transgene product (29, 30).”
BackgroundHigh IFN-γ Production of Individual CD8 T Lymphocytes Is Controlled by CD152 (CTLA-4)
Pandiyan, P., Hegel, J. K., Krueger, M., Quandt, D., & Brunner-Weinzierl, M. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2132 · Cited by 44
Activation induced changes in expression and structure of the IL-7 receptor on human T cells
Foxwell, B. M. J., Taylor-Fishwick, D. A., Simon, J. L., Page, T. H., & Londei, M. (1992) · International Immunology · doi:10.1093/intimm/4.2.277 · Cited by 42
Maximizing Antigen Targeting to the Proteasome for Gene-Based Vaccines
Andersson, H. A., & Barry, M. A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.035 · Cited by 39 · cited 1×
“It should be noted that GFP carries an epitope that is recognized by CD8+ T cells of the H-2d haplotype (27).”
BackgroundHonda, H., & Rostami, A. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.18.7007 · Cited by 36 · cited 1×
“org Volume 117 Number 12 December 2007 by rAAV vectors is most likely lower than that produced during a chronic viral infection and furthermore is restricted to the site of injection (76).”
BackgroundAAV-mediated gene transfer for hemophilia
High, K. A. (2002) · Genetics in Medicine · doi:10.1097/00125817-200211001-00012 · Cited by 31
Page, T. H., Willcocks, J. L., Taylor, D., & Foxwell, B. M. J. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.9.4753 · Cited by 29
Laouar, A., Manocha, M., Wan, M., Yagita∥, H., van Lier, R. A. W., & Manjunath, N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.652 · Cited by 27
Logan, G. J., Wang, L., Zheng, M., Cunningham, S. C., Coppel, R. L., & Alexander, I. E. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.09.072 · Cited by 26
Coenen, J. J. A., Koenen, H. J. P. M., van Rijssen, E., Boon, L., Joosten, I., & Hilbrands, L. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5240 · Cited by 21
Can genes transduced by adeno-associated virus vectors elicit or evade an immune response?
Wang, C.-H., Liu, D.-W., Tsao, Y.-P., Xiao, X., & Chen, S.-L. (2003) · Archives of Virology · doi:10.1007/s00705-003-0241-3 · Cited by 18
Analysis of Parvovirus mRNA by Sedimentation and Electrophoresis in Aqueous and Nonaqueous Solution
Carter, B. J. (1974) · Journal of Virology · doi:10.1128/jvi.14.4.834-839.1974 · Cited by 14 · cited 1×
“AAVs are single-stranded DNA parvoviruses that infect both dividing and nondividing cells (11).”
Background(2007) · Molecular Therapy · doi:10.1016/s1525-0016(16)44293-0 · Cited by 1
Research works printed but not linked: 2
- Steinman, 2006, Curr. Top. Microbiol. Immunol., 311, 17
- van Lunzen, J., et al. 2007. A Phase I study to evaluate the safety and immunogenicity of a recombinant adeno-associated virus vaccine. In 14th Conference on Retroviruses and Opportunistic Infections. February 25–28, 2007. Los Angeles, California, USA. Foundation for Retrovirology and Human Health. http://www.retroconference.org/2007.
Cited by
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
“They fail to eliminate the transduced muscle, do not respond to boost vaccination, and upregulate immunoinhibitory molecules such as PD-1.”
BackgroundProgress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Metadata
- Authors
- Lin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J.
- Affiliations
- The Wistar Institute (US)
- Corresponding author
- Ertl, Hildegund C.J.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-11-15
- Volume
- 117
- Issue
- 12
- Pages
- 3958-70
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2078325
- OpenAlex
- W2164754609
- Cited by
- 88
- References
- 75
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 3 · 2021: 2 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 7 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 6 · 2012: 5
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health
- U.S. Public Health Service (P01 A1055018-02)
- National Heart, Lung, and Blood Institute (P01HL078810)
- National Institute of Allergy and Infectious Diseases
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- recombinant adeno-associated virus vectors, HIV-1 Gag, CD8+ T cells, T cell proliferation, interferon-gamma, AAV serotypes, prime-boost vaccination, HIV-1 vaccine, antigen persistence, T cell dysfunction, vaccine immunogenicity
- MeSH terms
- Dependovirus, Adenoviridae, Animals, Genetic Vectors, Humans, Immunization, Secondary, Mice, Inbred BALB C, HIV-1, AIDS Vaccines, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Mice, gag Gene Products, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.